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This review summarizes the main findings of the French multicentre DAI-PP pilot programme, and discusses the related clinical and research perspectives. 
This project included retrospectively more than 5000 subjects with structural heart disease who received an implantable cardioverter defibrillator (ICD) for 
primary prevention of sudden cardiac death, and followed for a mean period of 3 years. This collaborative research programme led to 20 publications. Several 
useful and clinically relevant findings emerged from this cohort, which are summarized in this review. Firstly, our registry revealed the changing trends in 
primary prevention ICD implantation over the past decade, with increases in age at implantation and the proportions of cardiac resynchronization therapy, and 
female recipients. The occurrence of early complications after implantation remained significantly associated with global mortality (odds ratio 1.70; P = 0.003). 
Female recipients of resynchronization therapy had a lower incidence of appropriate therapies (hazard ratio 0.62; P < 0.001 versus males). Overall mortality 
was higher among patients with ischaemic compared with non-ischaemic cardiomyopathy (hazard ratio 1.31; P = 0.01); incidences of appropriate therapies 
were similar. During follow-up, 3.2% of ICD recipients had a heart transplantation. Looking at utility of ICD implantated after 80 years, 19.4% received at least 
one appropriate therapy before death. Compared with single-chamber ICD, dual-chamber ICD did not reduce rates of inappropriate therapies, and were 
associated with a higher rate of complications. Finally, this pilot phase have led to a prospective evaluation since May 2018, assessing ICD therapy in the 
primary and secondary prevention, in patients with structural and electrical heart diseases followed-up with a remote monitoring dedicated platform.  
 
Résumé  
Cet article résume les principaux résultats de la phase pilote du programme DAI-PP et discute ses perspectives scientifiques. Ce projet a inclus plus de 5000 
sujets ayant une cardiopathie et implantés d’un défibrillateur automatique implantable (DAI) en prévention primaire de la mort subite avec un suivi moyen de 3 
ans. Ce programme de recherche collaboratif a abouti à 20 publications dont les principaux résultats sont résumés dans cette revue. Premièrement, ce 
registre a évalué l’évolution des implantations de DAI sur la dernière décennie, décrivant une augmentation de l’âge à l’implantation, de la proportion de 
resynchronisation cardiaque, et de femmes implantées. La survenue d’une complication précoce était significativement associée à la mortalité globale (OR 
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1,70 ; P = 0,003). L’incidence des thérapies appropriées était plus faible chez les femmes implantées d’une resynchronisation (HR 0,62 ; P < 0,001 versus 
hommes). La mortalité globale était plus élevée chez les porteurs d’une cardiopathie ischémique comparé aux non-ischémiques alors que l’incidence des 
thérapies appropriées était similaire. Durant le suivi, 3,2 % des patients ont bénéficié d’une transplantation cardiaque. Chez les patients ≥ 80 ans à 
l’implantation, 19,4 % ont reçu au moins une thérapie appropriée avant leur décès. Enfin, comparé aux appareils mono-chambre, les DAI double-chambre ne 
réduisaient pas le taux de thérapies inappropriées et étaient associés avec un risque plus élevé de complications. Après cette évaluation pilote, un 
programme prospectif a été initié en France (mai 2018) visant à évaluer les DAI en prévention primaire et secondaire, chez des patients porteurs de 
cardiopathie structurelle et électrique, suivis en télécardiologie via une plateforme dédiée. 
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Sudden cardiac death remains a major mode of death in Western world [Ref sup 1 and 2]. Implantable cardioverter defibrillators (ICDs) for primary prevention 
of sudden cardiac death have been demonstrated to be associated with a significant reduction in overall mortality, among selected patients with dilated and 
ischaemic cardiomyopathies [1, 2]. Nevertheless, the implantation of such devices has the potential for numerous complications [3, 4]. Moreover, accurate 
prediction of sudden cardiac death is still a considerable challenge, and the number of patients implanted with a primary prevention ICD who will never 
experience ventricular arrhythmia represents both wasted effort and unnecessary risk, underlining the need for continuous improvements in the selection 
process for ICD candidates [5].  
 Although randomized controlled trials have given us a wealth of evidence, long-term data from the real-world setting are valuable and complementary. 
With this in mind, the pilot phase of the DAI-PP programme was conceived as a retrospective French multicentre registry aiming to assess the characteristics 
and outcomes of all patients implanted with an ICD for the primary prevention of sudden cardiac death between 2002 and 2012 (ClinicalTrials.gov Identifier: 
NCT#01992458), across 12 academic and private electrophysiology centres. All data were recorded retrospectively according to a specific protocol. Overall, 
5539 consecutive patients were included, and the mean follow-up was 3 years. This registry led to 20 publications, and gave insights into several practical 
aspects of ICD use in primary prevention. This paper summarizes the main findings from the different DAI-PP analyses, and puts these into perspective, to 
help to eventually optimize primary prevention of sudden cardiac death using ICD therapy. 
 
Main findings (Table 1) 
Trends in primary prevention ICD implantation over a decade  
As technology and clinical practice surrounding the use of primary prevention ICD implantation are in a state of constant evolution, the temporal trends in 
characteristics and outcomes of ICD therapy were assessed between 2002 and 2012 [6]. In addition to a shift in the type of device implanted, significant 
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increases were observed in mean age (from 61.5 ± 11.6 to 63.2 ± 10.9 years; P = 0.0016) and the proportions of cardiac resynchronization therapy (CRT) with 
an ICD (from 43.6% to 60.4%; P = 0.0001), non-ischaemic cardiomyopathy (NICM) (from 31.0% to 44.7%; P < 0.0001) and female recipients (from 11.4% to 
15.8%; P = 0.004). Reductions in annual mortality incidence (from 5.4% to 4.3%; P = 0.05) and appropriate therapy incidence (from 10.4% to 7.1%; P = 
0.0004) were seen over the decade. By contrast, the incidence of ICD-related late complications (> 30 days after implantation) increased significantly (from 
4.6% to 7.6%; P = 0.003). This analysis highlighted significant changes in the patterns of use and outcomes in primary prevention ICD implantation, with 
reductions in mortality and appropriate therapies, counterbalanced by an increase in complications. While the former is likely to be a reflection of advances in 
and better adherence to guideline-directed medical therapies, the latter is concerning, and may be the result of increased numbers of implantations in older 
patients with more co-morbidities. Of note, in this large cohort of primary prevention ICD recipients, more than a quarter were implanted without fulfilling 
proper guideline criteria, similar to rates reported in other large registries [Ref sup 3]. Despite a less severe clinical profile at implantation and lower mortality 
rates, off-guideline patients had, rather surprisingly, similar rates of appropriate therapies. These patients were also likely to benefit from their ICDs, underlying 
the need for a better risk stratification in the future. 
 
 
Special focus on specific groups: Women, advanced functional heart failure class and the elderly 
Through the DAI-PP project we were able to assess outcomes according to specific variables, such as sex, New York Heart Association (NYHA) class and 
age. In most ICD trials, women were markedly under-represented. In our registry, women constituted a minority of the recipients of an ICD as well (15.1%), 
53.8% of whom received CRT [7]. Compared with men, women presented a different clinical profile, with a significantly higher proportion of NICM (60.2% vs 
36.2%; P < 0.001), a wider QRS complex (QRS > 120 ms: 74.6% vs 68.5%; P = 0.003) a higher NYHA functional class and a lower prevalence of atrial 
fibrillation. During follow-up, female recipients of an ICD had a lower incidence of appropriate ICD therapies (hazard ratio [HR] 0.59, 95% confidence interval 
[CI] 0.45–0.76; P < 0.001) and all-cause death (HR 0.87, 95% CI 0.66–1.15; P = 0.324) than their male counterparts, whereas the rates of inappropriate 
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shocks and early complications were similar in both groups. Scientific data on sex-specific outcomes is still growing, and pooled data might allow to get 
enough power, to eventually lead to sex-specific ICD guidelines in the future [[8]Ref sup 4]. 
 Although guidelines use NYHA class in the decision process for ICD implantation, mortality benefit in NYHA class III patients (especially compared to 
NYHA class II) is a matter of debate [1, 2]. Analysis of outcomes by NYHA class in the DAI-PP database demonstrated that although patients in NYHA class 
III have higher overall mortality (HR per NYHA class 1.63, 95% CI 1.11–2.41; P = 0.014), driven by an increase in cardiovascular death, they experienced a 
similar incidence of appropriate ICD therapies [9]. Incidence of ICD-unresponsive sudden death remained very low, and was also similar across NYHA 
classes, supporting the efficacy of ICD in relatively advanced heart failure. 
 The benefit of primary prevention ICD implantation is also controversial in elderly patients, because of the greater competing risk of non-arrhythmic death. 
For this purpose, patients’ characteristics and outcomes were analysed in three age groups: 18–59 years; 60–74 years; and ≥ 75 years [10]. As expected, 
older patients exhibited higher global mortality after ICD implantation. However, rates of sudden death and appropriate device therapies were similar across 
age groups. Older age was independently associated with a higher rate of early postimplantation complications (odds ratio [OR] 1.28 for age 60–74 years; OR 
1.49 for age ≥ 75 years; P = 0.03) and a lower rate of inappropriate therapies. Among patients aged ≥ 80 years, 19.4% received at least one appropriate 
therapy before death [11. Our results might suggest that among well-selected older subjects with relatively few co-morbidities, as reflected in our study 
population, primary prevention ICD implantation may be of relevance. Nevertheless, the inherent limitations in interpreting observational data in this particular 
competing-risk situation call for randomized controlled trials to provide definitive answers. Meanwhile, a careful multidisciplinary evaluation is needed to guide 
patient selection for ICD implantation in the elderly population.  
 
Significant impact of early periprocedural complications  
To date, the extent to which early complications after ICD implantation are associated with morbidity and mortality at longer term, in daily practice, has only 
been addressed in limited populations. The DAI-PP project assessed the incidence and consequences of early complications (≤ 30 days) after ICD 
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implantation [12]. Overall, early complications occurred in 13.5% of patients, with the most frequent complications being bleeding related (hematoma, 35.9%) 
and lead dislodgment (20.7%). Independent factors associated with occurrence of early complications were severe renal impairment (OR 1.66; P = 0.02), age 
≥ 75 years (OR 1.01; P = 0.03), CRT (OR 1.58; P = 0.01) and anticoagulant therapy (OR 1.28; P= 0 .03). After adjustment, early complications remained 
associated with mortality (OR 1.70; P = 0.003) (Fig. 1). These results reinforce the impact of early complications, and particularly avoidance of pocket 
haematoma, which was the most frequent early complication. While recent guidelines demonstrated a high level of evidence regarding vitamin K antagonist 
management, scientific data is still limited regarding non-vitamin K antagonist oral anticoagulant management in the periprocedural period of implantable 
cardiac electronic devices [13]. 
 
Perioperative defibrillation testing  
Recent literature suggests that routine defibrillation testing does not improve defibrillation efficacy or reduce arrhythmic death [14]. Nevertheless, the impact of 
defibrillation testing had not been specifically evaluated in recipients of CRT with a ICD implanted for primary prevention of sudden cardiac death. Therefore, 
we compared outcomes between patients who underwent defibrillation testing and those who did not, immediately after the implantation of a CRT ICD [15]. 
Out of the 1516 patients, defibrillation testing was performed in 958 (63%) patients. All of the three perioperative deaths occurred in the group that had 
defibrillation testing, and were related to defibrillation testing itself. The adjusted incidence of overall mortality was lower in the group that had defibrillation 
testing (HR 0.6; P < 0.0001), mainly reflecting the less severe cardiac disease in this group (making patients more likely to be selected for defibrillation testing), 
rather than a lower rate of ICD-unresponsive sudden death during follow-up. Taken overall, our results do not encourage systematic defibrillation testing in 
recipients of CRT with a ICD.  
 
Outcomes comparison between NICM and ischaemic cardiomyopathy (ICM) 
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The benefit of primary prevention ICD implantation in NICM has been debated recently, and the evidence level for ICD implantation in NICM is considered to 
be lower than for ICM in the European Society of Cardiology guidelines [16, 17]. Consequently, the DAI-PP study group compared outcomes between 
recipients of an ICD implanted for primary prevention with NICM (40% of patients) and with ICM (60% of patients) [18]. Overall mortality was higher in the ICM 
group than the NICM group (adjusted HR 1.31; P = 0.01), and the increase in cardiac mortality in the ICM group was mainly the result of non-cardiovascular 
causes (P = 0.0002). The incidence of appropriate ICD therapy was similar in the two groups. These observational data appear to support the efficacy of ICD 
in NICM, similar to other recent registry data and meta-analyses [ref sup 8].  
 
CRT: Is an additional ICD always required? 
The DAI-PP project also collaborated with a large multicentre European cohort, assessing the added value of an ICD over CRT in ICM and NICM [19]. Overall, 
5307 consecutive patients with NICM or ICM underwent CRT implantation with (n = 4037) or without (n = 1270) a ICD. After a mean follow-up period of 41.4 ± 
29.0 months, patients with ICM had better survival when receiving CRT with a ICD compared with those who received CRT without a ICD (HR 0.76; P = 
0.005), whereas in patients with NICM, no such difference was observed (HR 0.92; P = 0.49) (Fig. 2). Outcome differences according to sex category were 
also assessed, and benefit from CRT with a ICD was seen in male patients (HR 0.78; P = 0.012), but not in female patients (HR 0.87; P = 0.43). These 
findings were confirmed in another collaborative work assessing sex-specific outcomes with the addition of a ICD to CRT [20]. These results reinforce the 
importance of careful patient selection, especially among women, to optimize the benefit and cost-effectiveness of an added ICD in patients with an indication 
for CRT. 
 In addition further analyses were carried out from a large European CRT consortium comprising French, UK, Czech and Swedish patients who received 
CRT implantation or upgrade between 2002 and 2012, in order to provide long term outcomes, especially with regard to the occurrence of sudden cardiac 
death, in CRT patients without and with defibrillator. Progressive heart failure death was found to represent the most frequent cause of death in patients 
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surviving the first five years after CRT implant. By contrast, SCD represented a very low proportion of late mortality irrespective of the presence of an ICD. 
[Ref sup 5]  
 
 
Reducing the ICD shock burden 
The benefits of ICD implantation in the primary prevention of sudden cardiac death are offset to some extent because of the morbidity conferred by both 
appropriate and, more importantly, inappropriate shocks. The MADIT-RIT trial suggested very-high-rate cut-off and long detection time strategies to reduce 
inappropriate shocks [21]. We assessed the real-world efficacy of a very-high-rate cut-off programming strategy in our registry, by comparing 500 patients 
programmed with a very-high-rate cut-off (VH-RATE group: monitor zone 170–219 beats/min; ventricular fibrillation zone ≥ 220 beats/min with 13 ± 4 detection 
intervals) with 1500 matched control patients programmed with standard one therapy or two therapy zones [22]. VH-RATE programming was associated with 
reductions in appropriate therapy (HR 0.40; P < 0.0001) and inappropriate shock risk (HR 0.42; P < 0.0001) (Fig. 3). Nevertheless, there was no significant 
difference in overall survival between the groups. Optimal ICD programming, which focuses on the reduction of therapies, could be a safe and effective 
strategy in preventing subsequent morbidity and/or mortality from ICD shocks. 
 
Efficacy of single-chamber versus dual-chamber ICDs 
Another putative way to reduce inappropriate shocks could be the implantation of an atrial lead, to enhance reliability of supraventricular arrhythmia 
discrimination. However, the benefit of dual-chamber versus single-chamber ICDs could be counterbalanced by a higher rate of complications related to dual-
chamber ICD implantation. Using the DAI-PP dataset, we compared 1258 recipients of single-chamber ICDs with 1280 recipients of dual-chamber ICDs [23]. 
While the rates of periprocedural complications were higher in the dual-chamber ICD group (12.1%) compared with the single-chamber ICD group (8.8%; P = 
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0.008), the proportions of appropriate therapies (24.7% vs 23.8%), inappropriate shocks (8.4% vs 7.8%) and all-cause mortality (12.4% vs 13.2%) were similar 
between groups (Fig. 4). Thus, our DAI-PP experience does not support the routine implantation of dual-chamber ICDs to reduce inappropriate therapies. 
 
Improving the benefit of ICD therapy by improving selection accuracy 
Better patient selection, particularly with regard to identifying those at high risk of non-arrhythmic death, may improve the cost-effectiveness of primary 
prevention ICD implantation [24]. In this context, a cause-of-death analysis was carried out in 2485 patients, to investigate the extent to which a prognostic 
score derived from a randomized controlled trial in patients with coronary artery disease was of potential interest in the real-world setting for patients with ICM 
and NICM [25]. The risk score included points for NYHA functional class III or greater, age > 70 years, QRS duration > 120 ms, atrial fibrillation and glomerular 
filtration rate < 60 mL/min. After a mean follow-up of 3.0 years, the overall mortality rate was 5.9 per 100 patient-years, which increased progressively with the 
number of risk factors. The higher mortality rate among patients with the highest scores resulted from an increase in non-arrhythmic mortality (from 2.1 to 14.8 
per 100 patient-years; P < 0.001), whereas the occurrence of appropriate ICD therapies did not change significantly across the categories. The C-statistic 
testing of the score was observed to be highly similar for patients with ICM (0.685) and NICM (0.658) and those receiving CRT (0.678). These findings 
underline the feasibility in the real-world setting of identifying patients who are at significant risk of non-arrhythmic death among those eligible for primary 
prevention ICD implantation. A careful analysis of the risk-benefit ratio and additional discussion with the patient would be warranted in such identified cases. 
 
Electrical storm in primary prevention recipients of an ICD  
The characteristics and risk of death in patients who developed electrical storm during follow-up were evaluated [26]. Occurrence of electrical storm was 
associated with poor prognosis, as the probability of death was higher after electrical storm (HR 3.77; P < 0.001). In the multivariable survival analysis, renal 
failure (HR 1.8; P = 0.007), left ventricular ejection fraction < 30% (HR 1.7; P = 0.03) and male sex (HR 2.3; P = 0.05) were associated with the occurrence of 
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electrical storm. These data underline the prognostic implications of electrical storm, which may be mitigated nowadays by advances in catheter ablation 
techniques and by neural modulation, and prevented in some extent with the optimization of pharmacological therapies. 
 
CRT response, survival and heart transplantation in recipients of an ICD  
Almost a third of patients with heart failure fail to respond to CRT. To help identify such patients, a simple clinical risk score called ScREEN was 
developed using the DAI-PP cohort, and then validated in an external cohort [27]. This score used the following variables: sex category; renal function; 
electrocardiogram/QRS width; ejection fraction; and NYHA class. External validation showed good calibration, accuracy, and discrimination (C-statistic 0.67), 
with CRT response increasing progressively from 37.5% in patients with a score of 0 to 91.9% in those with a score of 5 (P < 0.001). Finally, our real-world 
data support other findings from other groups. As expected, there were differences in the risk of death and probability of CRT response among comorbidity 
groups but, the burden of comorbidity did not appear to significantly influence the probability of response to CRT, despite a potentially smaller survival benefit 
in patients with ≥3 comorbidities. Although ICD implantation should be carefully considered in patients with multiple comorbidities, CRT should not be withheld 
in this context of heart failure patient with enlarged QRS. [Ref sup 6]  
 
 While ICDs are not recommended for patients with an expected survival of < 1 year, the factors in real life associated with such an outcome have not 
been well studied. We assessed the prevalence and factors associated with survival of ≤ 1 year among patients implanted with an ICD [Ref sup 7]: 230 out of 
5457 (4.2%) patients survived for ≤ 1 year. Causes of death were similar in those who survived ≤ 1 year versus > 1 year, and patients who survived for ≤ 1 
year had fewer appropriate and inappropriate ICD therapies than patients who survived for > 1 year (respectively, 14% vs 23% [P = 0.004] and 2% vs 7% [P = 
0.009]). In the multivariable analysis, older age, higher NYHA class (≥ III), atrial fibrillation and lower left ventricular ejection fraction were significantly 
associated with survival for ≤ 1 year. 
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 Finally, the frequency, characteristics and outcomes of primary prevention recipients of an ICD who undergo heart transplantation during follow-up were 
described in the DAI-PP study [28]: 176 (3.2%) patients underwent heart transplantation. The median duration between ICD implantation and heart 
transplantation was 484 days (interquartile range 169–1117 days). The incidence of appropriate ICD therapies was relatively high in patients who had a heart 
transplantation compared with those who did not (92.7 vs 76.1 per 1000 person-years; P = 0.64), reinforcing the importance of specific cardiac rhythm 
management for these patients, while they await heart transplantation. 
 
Conclusions 
The pilot phase of DAI-PP programme has provided valuable information on several practical and clinically relevant aspects of primary prevention ICD 
implantation in the real-world population of patients with ischaemic and non-ischaemic cardiomyopathy. This pilot led to a prospective evaluation which started 
in May 2018, assessing ICD therapy in the primary and secondary prevention, in patients with structural and electrical heart diseases, with a remote 
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Figure 1. Survival curves for mortality according to early complication occurrence. 
 
Figure 2. Survival curves comparing cardiac resynchronization therapy with a ICD (CRT-D) versus cardiac resynchronization therapy with a pacemaker (CRT-
P), using Cox regression with adjustment on the propensity score and all mortality predictors. CI: confidence interval; HR: hazard ratio; N: number. 
 
Figure 3. Survival probability of inappropriate shock occurrence according to implantable cardioverter ICD settings. VH-RATE: very-high-rate group; 1-zone: 
one therapy zone; 2-zone: two therapy zone.  
 
Figure 4. Proportions of appropriate and inappropriate therapies during follow-up, according to the type of device: single-chamber ICD (SC-ICD) versus dual-
chamber ICD (DC-ICD).  
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Table 1 Main findings. 
DAI-PP main findings Over a decade, age at implantation and the proportions of CRT implantations, NICM and female recipients have increased [6].  
 Compared with males, female recipients of an ICD have a 0.59-fold lower incidence of appropriate ICD therapies [7].  
 Although patients in NYHA class III have a higher overall mortality, driven by an increase in cardiovascular death, they experience a 
similar incidence of appropriate ICD therapies [8].  
More than a quarter were implanted without fulfilling proper guideline criteria.  Despite a less severe clinical profile at implantation and 
lower mortality rates, off-guideline patients had, rather surprisingly, similar rates of appropriate therapies [Ref sup 3]. 
 After ICD implantation, older patients exhibit higher global mortality, but 19.4% experience at least one appropriate therapy before 
death, and rates of appropriate therapies are similar overall across age groups [10].  
 Overall, long-term mortality was lower among recipients of CRT with a ICD who had undergone perioperative defibrillation testing (HR 
0.6); however, this mainly reflected their less severe cardiac disease [14]. 
 Early complication after ICD implantation is associated with a 1.7-fold higher risk of mortality; factors associated with early 
complications are severe renal impairment, age ≥ 75 years, CRT and anticoagulant therapy [11].  
 Programming a very high ventricular tachycardia and fibrillation cut-off rate is associated with a reduction in appropriate therapies and 
inappropriate shock [22]. 
 Compared with single-chamber ICDs, dual-chamber ICDs do not reduce rates of inappropriate therapies, and are associated with a 
higher rate of complications [23]. 
 A risk score including NYHA class ≥ III, age > 70 years, QRS duration > 120 ms, atrial fibrillation and GFR < 60 mL/min allows 
identification of patients at risk of non-arrhythmic death, who might not benefit from ICD therapy [25]. 
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 Electrical storm among patients with an ICD is associated with a 3.77-fold higher risk of death [26]. 
DAI-PP collaborations 
main findings 
Patients with ICM had better survival when receiving CRT with a ICD compared with those who received CRT alone; no such 
difference was observed in patients with NICM [19].  
 A simple clinical risk score called ScREEN, using sex category, renal function, electrocardiogram/QRS width, ejection fraction and 
NYHA class variables, is able to identify patients who will not respond to CRT [27]. 
 In patients with an indication for CRT, the addition of an ICD conveys additional benefit in well-selected male patients, but possibly 
not in female patients [20]. 
The burden of comorbidity did not appear to significantly influence the probability of response to CRT, despite a potentially 
smaller survival benefit in patients with ≥3 comorbidities. Although ICD implantation should be carefully considered in patients with 
multiple comorbidities, CRT should not be withhold in this context of heart failure patient with enlarged QRS. [Ref sup 6]  
Progressive heart failure death was found to represent the most frequent cause of death in patients surviving the first five years 




CRT: cardiac resynchronization therapy; GFR: glomerular filtration rate; HR: hazard ratio; ICD: implantable cardioverter defibrillator; ICM: ischaemic 
cardiomyopathy; NICM: non-ischaemic cardiomyopathy; NYHA: New York Heart Association. 
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